Impacts__O derive__O from__O a__O long__O term__O concerted__O molecular__O and__O classical__O research__O programme__O led__O by__O the__O UoL__B-ORG which__O has__O directly__O led__O to__O improved__O protection__O of__O poultry__O against__O serious__O disease,__O thus__O improving__O the__O efficiency__O of__O meat__O and__O egg__O production.__O
The__O beneficiaries__O are__O the__O protected__O animals__O in__O terms__O of__O animal__O welfare,__O poultry__O farmers__O globally__O in__O terms__O of__O economic__O efficiency__O and__O the__O general__O public__O in__O terms__O of__O economic__O high__O quality__O protein__O availability__O from__O meat__O and__O eggs,__O i.e.__O
food__O security.__O
Economic__O and__O health__O impacts__O The__O Liverpool__B-ORG vaccine__O has__O been__O important__O in__O global__O AMPV__B-ORG control.__O
It__O is__O one__O of__O only__O two__O subtype__O A__O live__O vaccines__O used__O globally.__O
Its__O profile__O is__O summarised__O in__O the__O DEFRA__B-ORG 2012__O summary__O sheet__O [7].The__O continued__O use__O of__O the__O vaccine__O is__O enhanced__O by__O the__O Liverpool__B-ORG team's__O on-going__O research__O into__O its__O applications__O and__O usage,__O thus__O helping__O ensure__O the__O product's__O safety__O and__O efficacious__O use.__O
It__O is__O only__O the__O effective__O application__O AMPV__B-ORG vaccine__O in__O hatcheries__O and__O on__O farms__O that__O prevents__O the__O severe__O disease__O and__O losses__O seen__O prior__O to__O vaccine__O introduction.__O
UoL__O researchers__O have__O been__O key__O to__O maintaining__O this__O major__O impact__O on__O disease__O protection__O in__O a__O major__O food__O species.__O
Eight__O million__O doses__O of__O the__O vaccine__O were__O sold__O in__O Europe,__B-LOC Africa__I-LOC and__O the__O Middle__B-LOC East__I-LOC in__O the__O last__O financial__O year,__O much__O comprising__O UK__B-LOC turkeys__O (production__O approx__O 17__O million__O per__O year)__O and__O to__O a__O lesser__O extent__O in__O France.__B-LOC
This__O is__O a__O 20%__O sales__O increase__O over__O the__O previous__O year,__O an__O indication__O of__O both__O the__O importance__O of__O the__O disease__O and__O the__O performance__O of__O the__O vaccine.__O
The__O figure__O does__O not__O include__O Asia/Pacific__B-MISC and__O South__B-LOC America__I-LOC (particularly__O Brazil)__B-ORG which__O are__O the__O biggest__O markets__O for__O the__O vaccine.__O
The__O Liverpool__B-ORG team's__O on-going__O research__O has__O allowed__O for__O the__O development__O of__O improved__O guidelines__O allowing__O the__O poultry__O industry__O to__O protect__O essential__O food__O production__O and__O maximise__O profit.__O
[9,10,12,13]__O Vaccine__O developments__O arising__O from__O the__O UoL__B-ORG research__O that__O have__O had__O an__O impact__O on__O the__O industry__O primarily__O by__O increasing__O effectiveness__O of__O the__O use__O of__O the__O vaccine__O since__O 2008__O have__O included:__O Demonstration__O of__O reversion__O to__O virulence__O on__O farms__O of__O the__O Zoetis__O clone__O K__O vaccine__O in__O 2006__O led__O to__O the__O UoL__B-ORG demonstrating__O in__O 2011__O that__O such__O reverted__O virus__O could__O circulate__O in__O the__O environment__O and__O in__O 2012__O to__O the__O UoL's__B-MISC demonstration__O that__O a__O Merial__O subtype__O B__O vaccine__O could__O also__O revert__O to__O virulence__O on__O farms.__O
The__O Liverpool__B-ORG group__O now__O advises__O at__O national__O (British__B-ORG Veterinary__I-ORG Poultry__I-ORG Association)__I-ORG and__O international__O (World__O Veterinary__O Poultry__B-PER Association)__I-PER poultry__O veterinary__O meetings__O that__O all__O AMPV__B-ORG vaccines__O should__O be__O administered__O more__O effectively__O so__O as__O to__O avoid__O unvaccinated__O birds__O becoming__O infected__O with__O potentially__O reverting__O shed__O vaccine__O virus.__O
Changes__O of__O farming__O practice__O resulted,__O especially__O in__O Europe.__B-LOC
More__O careful__O vaccine__O application__O became__O the__O standard,__O so__O as__O to__O avoid__O residual__O unvaccinated__O birds__O being__O infected__O with__O vaccine__O shed__O from__O littermates.__O
Furthermore,__O multi-age-site-farms__O have__O fallen__O out__O of__O usage__O because__O of__O the__O greater__O level__O of__O susceptibility__O of__O young__O birds__O to__O any__O vaccine__O virus__O passaged__O in__O the__O environment.__O
As__O a__O result,__O the__O current__O MSD__B-ORG product__O advice__O relating__O to__O their__O AMPV__B-MISC Nobilis__I-MISC TRT__I-MISC live__O vaccine,__O states__O "The__O vaccine__O virus__O spreads__O and__O shows__O some__O reversion__O to__O virulence__O on__O bird__O to__O bird__O passage.__O
For__O these__O reasons__O its__O use__O is__O not__O recommended__O on__O multi-age__O sites.__O
Correct__O administration__O is__O important__O ..."__O [8,9,10,12,13].__O
The__O UoL__O discovered__O that__O maternal__O antibody__O did__O not__O block__O vaccination.__O
This__O led__O to__O adoption__O of__O one-day-old__O hatchery__O vaccination__O where__O previously,__O administration__O had__O been__O later__O on__O the__O farm.__O
This__O is__O formalised__O in__O the__O DEFRA__B-MISC summary__O sheet__O for__O the__O Liverpool__B-ORG developed__O clone__O K__O vaccine__O (Zoetis,__B-ORG Poulvac__I-ORG TRT)__I-ORG [7__O (page__O 1),9].__O
The__O question__O of__O matching__O AMPV__B-ORG vaccine__O subtype__O (A__B-ORG or__O B)__O to__O the__O prevalent__O field__O subtype__O has__O been__O debated__O since__O the__O discovery__O of__O subtypes__O in__O 1993.__O
Some__O parties,__O especially__O vaccine__O manufacturers,__O downplayed__O the__O issue,__O even__O though__O introduction__O of__O subtype__O B__O vaccine__O to__O the__O UK__B-LOC in__O 1995__O to__O combat__O the__O first__O UK__B-LOC incidences__O of__O subtype__O B,__B-ORG led__O to__O a__O large__O improvement__O in__O disease__O control__O (based__O on__O research__O by__O Naylor__B-ORG while__O at__O IAH__B-LOC Compton).__I-LOC
More__O influentially,__O from__O 2008__O to__O 2010__O Liverpool/Bologna__B-LOC studies__O (published__O 2010)__O conclusively__O proved__O that__O even__O small__O differences__O within__O a__O subtype__O had__O large__O effects__O on__O induced__O protection__O [2].__O
Currently__O AMPV__O vaccines__O of__O the__O correct__O subtype__O are__O favoured__O where__O the__O dominating__O field__O subtype__O is__O known__O [11].__B-ORG
The__O UoL__B-MISC showed__O in__O 2010__O that__O the__O continuous__O use__O of__O a__O single__O AMPV__B-MISC vaccine__O (Merial__B-PER Aviffa/Rhinovax)__I-PER in__O Italy__B-LOC had__O led__O to__O evolution__O of__O field__O viruses__O in__O circulation__O which__O avoided__O previously__O protective__O immunity.__O
This__O showed__O that__O exclusive__O use__O of__O a__O single__O vaccine__O type__O should__O be__O avoided__O and__O work__O has__O been__O presented__O to__O Italian__B-MISC veterinarians__O advising__O avoiding__O this__O practice__O who__O now__O avoid__O this__O practice__O where__O possible__O [9].__B-ORG
For__O some__O time__O it__O had__O been__O noticed__O that__O following__O vaccination__O the__O AMPV__B-ORG antibody__O might__O be__O absent,__O even__O though__O field__O survey__O evidence__O suggested__O that__O the__O birds__O were__O protected.__O
Without__O the__O UoL's__B-MISC discovery__O that__O an__O AMPV__B-ORG induced__O antibody__O responses__O was__O irrelevant__O to__O protection__O and__O frequently__O absent,__O the__O use__O of__O AMPV__B-ORG vaccines__O might__O have__O much__O reduced,__O thus__O reducing__O disease__O control__O [13].__B-ORG
In__O ovo__O vaccination__O proved__O effective__O in__O producing__O an__O earlier__O onset__O of__O immunity.__O
At__O the__O present__O time__O commercial__O restrictions__O have__O limited__O this__O to__O approach__O to__O small__O scale__O use__O [9].__O
